Ooni Koda
  1. Home
  2. /
  3. Newsfeed
  4. /
  5. Survey: Only 17% accessibility rate for Romanians to...

Survey: Only 17% accessibility rate for Romanians to new medicines approved at European level in 2019-2022

July 18, 2024

  Romanians have access to only 17% of the medicines approved at European level in the period 2019-2022, in 2023, no new medicines were unconditionally subsidised in our country, and in 2024 only 28 new medicines were included in the list of those subsidised, according to data from the study of the European Federation of Pharmaceutical Industries and Associations (EFPIA) on the Indicator of Access to Innovative Medicines Patients W.A.I.T. (Waiting to Access Innovative Therapies) for 2023.The Romanian Association of International Manufacturers of Medicines (ARPIM) made public on Thursday a series of data from three reports published in June 2024 by EFPIA, data collected from 36 countries (27 from the EU and 9 from outside the EU) that provide information on the 167 innovative medicines with centralized marketing authorization in the period 2019-2022.Dr. Ioana Bianchi, Director of Foreign Affairs at ARPIM, said that, according to the study data, in Romania, the availability rate of oncological drugs was 19% (out of the 48 that received European approval between 2019 and 2022, only 9 were available in Romania on January 5, 2024) as well as in the case of "orphan" drugs (drugs dedicated to the treatment of rare diseases) which was also 19%.Out of 167 innovative medicines that received approval from the European Medicines Agency (EMA) between 2019 and 2022, only 29 medicines were available in Romania on 5 January 2024. No medicine approved at European level in 2022 was subsidised in Romania on January 5, 2024.The drop is dramatic compared to last year's similar study, which showed an availability rate of 30% (51 drugs), the study data also highlights.As for the access time, i.e. the time from approval by the European Medicines Agency (EMA) to availability in Romania, it is 778 days, while German patients, for instance, have access to state-of-the-art medicines in just 126 days, according to the data presented by Dr. Bianchi.In our country, the main reasons why pharmaceutical companies have to wait to submit their evaluation files are: the evaluation criteria, the technical and human infrastructure necessary for diagnosing diseases, so the average time for submitting files is 86 days, but the average time for a reimbursement decision is 563 days, the data of the said study reads.  

Read in full - click here
Romania’s government advances law on magistrates’ pensions in Parliament

Romania’s government has assumed responsibility in Parliament for legislation reforming magistrates’ pensions, prime minister Ilie Bolojan announced on December 2. He said the draft law had received the opinion of the High Court of Cassation and Justice, noting that the court’s assessment was negative. It is the government’s second attempt to have the bill promulgated, […]

Private school network Romania Education Alliance accelerates national expansion plan

Romania Education Alliance (REA), the first private school network in the country, announced it has exceeded the milestone of 1,000 students enrolled across its member schools just one year after launch. "The fact that we surpassed 1,000 students in our very first year of activity shows that the REA model addresses a real need in […]

Mozaik Investments gets permit to take over Bucharest-based Genesis College

Genesis College, one of the largest private educational institutions in Romania, announced the regulatory approval of the transaction through which the investment firm Mozaik Investments becomes its majority shareholder. The transaction, signed at the end of July, received all necessary approvals from the Competition Council on November 25, and, formally, the entire investment procedure is […]

Brasov municipality takes EUR 30 mln EBRD loan for energy efficiency upgrades

The European Bank for Reconstruction and Development (EBRD) is lending up to EUR 29.9 million to the Romanian city of Brasov to finance energy efficiency upgrades in public buildings, initiating the city’s participation in the Bank’s flagship EBRD Green Cities programme. The Bank’s investment will fund the renovation of up to 20 public buildings, including […]

JW Marriott Bucharest Grand Hotel Unveils “The Grand Countdown” — A Timeless New Year’s Eve Celebration

This festive season, JW Marriott Bucharest Grand Hotel invites guests to embrace the extraordinary and transform each moment into a lasting memory. On New Year’s Eve, the hotel unveils The Grand Countdown — a luminous celebration of new beginnings, thoughtfully crafted across four distinctive venues, each with its own character and atmosphere. The night begins […]

Akhmetov’s Metinvest to take over Romanian pipe mill ArcelorMittal Tubular Products Iași

The European Commission has approved, under the EU Merger Regulation, the acquisition of sole control over ArcelorMittal Tubular Products Iași (AMTP Iași) by Metinvest B.V. of the Netherlands, part of the Ukrainian steel and mining group owned by Rinat Akhmetov, New Voice of Ukraine reported last week. Metinvest has...